Oncimmune Holdings plc has placed and converted debt into equity
November 2024 — Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Talk to the deal team
Related deals
OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value
OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.
Learn moreIndigo Capital has acquired a minority stake in Vivason
Indigo Capital has acquired a minority stake in Vivason, a leading network of hearing care centers, to support the company’s growth and enable management to increase its ownership stake.
Learn moreVerdane has completed the acquisition of Augmentum Fintech
Following the acceptance of its offer and subsequent shareholder approval, Augmentum Fintech plc has been acquired by Verdane Advisors AS.
Learn more